<DOC>
	<DOCNO>NCT02345057</DOCNO>
	<brief_summary>This study randomize , placebo-controlled , double-blind , multi-center study evaluate efficacy safety different dose CS-3150 compare placebo Japanese Type 2 Diabetes Mellitus Microalbuminuria . The Primary endpoint change baseline urinary albumin creatine ratio ( UACR ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CS-3150 Japanese Type 2 Diabetic Subjects With Microalbuminuria</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Subjects type 2 diabetes mellitus Male female subject age 20 year old informed consent Subjects urinary albumin creatine ratio ( UACR ) ≥ 45 mg/g Cr &lt; 300 mg/g Cr Estimated glomerular filtration rate creatinine ( eGFRcreat ) ≥ 30 mL/min/1.73 m^2 Subjects treat angiotensinconverting enzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) least 3 month prior treatment period Type 1 diabetes HbA1c ( NGSP ) &gt; =8.4 % Secondary glucose intolerance Subjects diagnose nondiabetic nephropathy Nephrotic syndrome Secondary hypertension malignant hypertension Serum potassium level follow category : For subject eGFRcreat ≥ 45 mL/min/1.73 m^2 , serum potassium level &lt; 3.5 mEq/L ≥ 5.1 mEq/L ; For subject eGFRcreat ≥ 30 mL/min/1.73 m^2 &lt; 45 mL/min/1.73 m^2 , serum potassium level &lt; 3.5 mEq/L ≥ 4.8 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
	<keyword>CS-3150</keyword>
	<keyword>Japanese</keyword>
</DOC>